Suggested remit: To appraise the clinical and cost effectiveness of obeticholic acid within its marketing authorisation for treating liver fibrosis in people with non-alcoholic steatohepatitis.
Following on from information provided to NICE by the company in June 2022, the appraisal of Obeticholic acid for treating liver fibrosis in people with steatohepatitis [ID1645] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
- Status:
- Discontinued
- Decision:
- Prioritised
- Process:
- TA
- ID number:
- 1645
Project Team
- Project lead
- Emily Richards
Email enquiries
If you have any queries please email scopingta@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 01 May 2026 | Discontinued. Following on from information provided to NICE by the company in June 2022, the appraisal of Obeticholic acid for treating liver fibrosis in people with steatohepatitis [ID1645] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 16 July 2021 | Note added to the project documents |
| 15 January 2021 | Note added to the project documents |
| 15 January 2021 | In progress. Topic is in progress |
| 09 September 2020 | Note added to the project documents |
| 07 May 2020 | Schedule affected by COVID-19. Topic update: this appraisal has not been defined as therapeutically critical. The appraisal will therefore be paused. At this stage, we are unable to provide alternative timelines as to when the appraisal may be re-started but we will provide an update when this information is available. |
| 13 March 2020 (14:00) | Scoping workshop (Manchester) |
| 20 January 2020 - 17 February 2020 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
For further information on our processes and methods, please see our CHTE processes and methods manual